We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Kirsty
Olsen
kirsty.olsen@ncl.ac.uk
Dr
John-Paul
Taylor
john-paul.taylor@ncl.ac.uk
Other degenerative diseases of the nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Dementia with Lewy bodies (DLB) is the second to third most common form of dementia. A core symptom of DLB is cognitive fluctuations, which refers to brief episodes of confusion, and problems with attention and communication. This symptom can have a negative impact upon patients and their carers/families. Whilst up to 90% of people with DLB have the symptom of cognitive fluctuations, it is not currently known what causes them and this prevents the accurate and reliable measurement of this symptom.
Overall, the aims of this project are to: 1) better understand cognitive fluctuations, by measuring changes in attention and thinking over an extended period of time, and 2) examine whether sleep/sleepiness is associated with cognitive
fluctuations, given the close relationship between sleep and attention/memory.
Twenty-four people with DLB, 24 with Alzheimer’s dementia and 24 control individuals, will complete attention, memory and sleep assessments. We will also measure their cognitive fluctuations and sleep habits using questionnaires and computerised tests over one week. People will also complete a laboratory visit where they will complete a range of computerised attention tests, and a short, non-invasive type of brain stimulation assessment, whilst having their brain activity measured.
Overall, this study will help us to: 1) understand the cause of cognitive fluctuations in DLB; 2) develop more sensitive clinical and research tools to measure cognitive flucutations, and 3) examine whether sleep is an important contributor to this symptom.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Participants will be excluded on the basis of the following: • Metallic implants in the head/neck area, or other electronic implants of any type (including pacemakers) • A history of other neurological illness including, but not limited to stroke, intracerebral pathology and epilepsy. • The presence of, or a history of, delirium. • A history of excess alcohol intake. • Presence of severe disease and significant physical co-morbidities • The presence of relevant visual impairments with the potential to interfere with attentional or visuoperceptual testing, or moderate-to-severe visual impairment secondary to glaucoma, cataract or macular degeneration. • Psychotropic and other medications which may significantly interfere with cognitive & TMS-EEG testing (including but not limited to antipsychotics, sedative antidepressants, benzodiazepines except low dose when used as hypnotics or treatment for REM-sleep behaviour disorder, and centrally acting anticholinergic drugs) • Any contraindications to MRI scanning, including but not limited to the presence of metal fragments in eyes, claustrophobia, an inability to lie flat for scanning.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by CUMBRIA, NORTHUMBERLAND, TYNE AND WEAR NHS FOUNDATION TRUST and funded by ALZHEIMER'S RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 42750
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
